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Letter to the EditorIn vivo imaging reveals increased
eosinophil uptake in the lungs
of obese asthmatic patientsTo The Editor:
Eosinophils play an important pathogenic role in pulmonary
and systemic conditions, including eosinophilic asthma and
eosinophilic granulomatosis with polyangiitis.1,2 Although
progress has been made in understanding the mechanisms
responsible for the activation of these cells, existing biomarkers
of eosinophilic inflammation are indirect and/or invasive and do
not always correlate with tissue eosinophilia. Hence, there is a
need to develop noninvasive biomarkers of tissue eosinophilia.
We have previously demonstrated the capacity of single photon
emission computed tomography (SPECT) to quantify neutrophil
uptake into the lungs of patients with chronic obstructive
pulmonary disease.3 We sought to determine whether this
methodology could be used to quantify eosinophil kinetics
and pulmonary uptake, which may differ among diseases
characterized by eosinophilic inflammation. In particular, the
role of the eosinophil in asthma with obesity, a distinct asthma
endotype associated with increased severity,4 is controversial.
We hypothesized that injection of radiolabeled eosinophils,
coupled with SPECT/CT, would reveal changes in eosinophil
kinetics in patients compared with healthy volunteers.
To determine the initial distribution of eosinophils, and to
ensure that the reinjected cells had not been activated, planar
gamma camera imaging was performed following injection
of technetium-99m–labeled eosinophils. These scans were
performed in healthy volunteers, patients with asthma, and
patients with focal eosinophilic inflammation (Fig 1, A; see
Tables E1 and E2 in this article’s Online Repository at
www.jacionline.org). The initial transit of radiolabeled
eosinophils through the lung was similar in all subjects
(Fig 1, B and C). We generated a ‘‘first-pass’’ transit curve to
calculate the time taken for the initial bolus of eosinophils to
transit from the right ventricle across the pulmonary
circulation (see Fig E1 in this article’s Online Repository at
www.jacionline.org). This value was constant across all study
groups (Fig E1, B). The 45-minute blood recovery values
(Fig 1, D) did not differ between the study groups and,
importantly, were comparable to published levels for
unmanipulated radiolabeled eosinophils from healthy volunteers,
indicating that the reinjected eosinophils were nonactivated.5 As
predicted,5,6 circulating eosinophils accumulated rapidly within
the liver and spleen, most likely within known marginated
intravascular pools (Fig 1, E-G).
To measure the time-dependent uptake of radiolabeled
eosinophils from the blood into the lungs (‘‘pulmonary uptake’’),
serial images were acquired using SPECT/CT (Fig 1, H) and
Patlak-Rutland analysis undertaken (see Fig E2 in this article’s
Online Repository at www.jacionline.org). As shown in Fig 1, I,
pulmonary uptake was significantly increased in patients with focal
eosinophilic inflammation (0.002 mL/min/mL; P5 .02) compared 2018 The Authors. Published by Elsevier Inc. on behalf of the American Academy of
Allergy, Asthma & Immunology. All rights reserved. This is an open access article
under the CC BY license (http://creativecommons.org/licenses/by/4.0/).with healthy volunteers (0.0003mL/min/mL). Therewas a trend to-
ward increased pulmonary uptake in patients with asthma
(0.0008 mL/min/mL; P 5 .14). However, conversion of this rate
of uptake to an absolute whole lung eosinophil migration value
by multiplying with the peripheral blood eosinophil count
revealed the full extent of eosinophil accumulation by the lungs;
patients with focal eosinophilic lung inflammation and subjects
with asthma had higher rates of eosinophil migration compared
with healthy volunteers (32 eosinophils/min/mL) (Fig 1, J). The
extent of eosinophil migration in patients with asthma did not
correlate with lung function or fractional nitric oxide (FENO)
(see Figs E3 and E4 in this article’s Online Repository at
www.jacionline.org).
To determinewhether this technique could reveal differences in
eosinophil kinetics between asthma endotypes, we stratified
patients with asthma as obese (body mass index >_30 kg/m2) or
nonobese (body mass index < 30 kg/m2) (Fig 2, A; see Table
E3 in this article’s Online Repository at www.jacionline.org),
and compared their eosinophil uptake. As shown in Fig 2, B, pul-
monary uptake was increased in obese patients with asthma
(0.001 mL/min/mL) compared with nonobese patients with
asthma (0.0003 mL/min/mL; P 5 .02). This effect was not
explained by an increase in the early retention of eosinophils in
the lung because the first-pass mean transit time was faster in
eosinophils of obese patients with asthma compared with
eosinophils of nonobese patients with asthma (P 5 .038)
(Fig 2, C). Furthermore, the 45-minute postinjection eosinophil
recovery values and peripheral blood eosinophil counts were
also similar (see Fig E4, A and B, in this article’s Online
Repository at www.jacionline.org). In a parallel but separate
group of subjects with asthma (Fig 2, D), stratified in an identical
manner to the SPECT/CT cohort, the bronchial submucosal
eosinophil count was significantly elevated in obese patients
with asthma compared with nonobese patients with asthma
(P 5 .024) (Fig 2, E and F). The epithelial eosinophil count,
sputum eosinophil count, peripheral blood eosinophil count,
FENO levels, and IgE levels were not significantly different
between patients with asthma with and without obesity (Figs E3
and E4).
The impact of antieosinophil therapies on eosinophil
trafficking is poorly understood. Inhaled corticosteroids are the
mainstay treatment for asthma and reduce the number of
eosinophils in sputum and bronchial biopsies. Biological
therapies such asmepolizumab2 reduce blood and lung eosinophil
counts, but their effects on eosinophil trafficking are unknown.
We anticipate that in vivo imaging of eosinophils will inform
the development of these therapies, and shed light on the
mechanisms controlling eosinophil migration.
We quantified eosinophil uptake from the blood to the lungs
and demonstrated increased eosinophil migration to the lungs in
our cohort with asthma relative to healthy controls. Although
eosinophil migration in part reflects the peripheral blood
eosinophil count, our methodology localizes inflammation and
quantifies the migration to the ‘‘whole lung’’ parenchyma,
providing information that cannot be obtained from the blood
cell count alone.7We observed that eosinophil uptake is enhanced
in obese patients with asthma compared with nonobese patients
with asthma, in agreement with our histology study. These results1
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FIG 1. Early organ distribution and lung uptake of technetium-99m–labeled eosinophils. A, Participants in
the scanning protocols. B, Time-course of radioactivity in the right lung following reinjection of
technetium-99m–labeled eosinophils. C, Half-life of technetium-99m–labeled eosinophil activity in the
lungs. Median with interquartile range (Mann-Whitney U test). D, Proportion of technetium-99m–labeled
eosinophils remaining in the blood 45 minutes after reinjection. Median with interquartile range
(Mann-Whitney U test). E, Gamma camera image 5 minutes (left) and 40 minutes (right) after reinjection
of technetium-99m–labeled eosinophils in a healthy volunteer. Posterior images show accumulation in
the right lung (RL), left lung (LL), liver (L), and spleen (S). F and G, Distribution of radioactivity in the liver
(green) and spleen (black) following reinjection of technetium-99m–labeled eosinophils. Data showmedian
with interquartile range in healthy volunteers (Fig 1, F) and patients with asthma (Fig 1, G); *P < .05,
**P < .01, and ***P < .001 compared with peak liver or peak spleen radioactivity (Kruskal-Wallis with
Dunn posttest). P 5 .009 compared with healthy liver radioactivity at 17 minutes (Mann-Whitney U test).
H, Transaxial SPECT images. Images show accumulation in the RL and LL (outlined by white lines) 6 hours
after reinjection. Pulmonary uptake (I) and pulmonary migration (J) of technetium-99m–labeled
eosinophils. Median with interquartile range (Mann-Whitney U test).
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2 LETTER TO THE EDITORchallenge the current dogma that asthma with obesity is
associated with noneosinophilic inflammation (demonstrated by
a low sputum eosinophil count),4 and we propose that the
bronchial eosinophil count and sputum eosinophil count are
uncoupled.8
Our study has some limitations. First, 50% of our cohort with
asthma (studied in the imaging protocol) was recruited from
primary care, and hence had not undergone in-depth phenotyping,
and only 3 patients with asthma had a clearly eosinophilic
phenotype based on FENO and peripheral eosinophil count.
Second, although we have previously published a rigorous assess-
ment of the reinjected eosinophils,5 we cannot absolutely exclude
subtle changes in cell function due to cell isolation and labeling.In conclusion, SPECT/CT imaging using radiolabeled
eosinophils provides evidence that eosinophil uptake can be
quantified in the lungs and is enhanced in obese patients with
asthma compared with nonobese patients with asthma. This
finding has important implications for the role of eosinophils in
obese patients with asthma and for selecting patients for targeted
therapy in the context of type 2 inflammation.
We thank Dr Robin Gore and Dr James Nathan for help in recruiting
volunteers and Dr Latifa Chachi for her advice and practical expertise in
microscopy. We are grateful to the staff within the Nuclear Medicine
Department at Addenbrooke’s Hospital and the National Institute for Health
Research Cambridge Clinical Research Facility.
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FIG 2. SPECT/CT quantification of pulmonary eosinophil uptake and bronchial biopsy eosinophil counts in
obese and nonobese patients with asthma. A, Participants in the scanning cohort. B, Pulmonary eosinophil
uptake of patients with asthma, stratified by body mass index as obese or nonobese. Mean 6 SEM
(unpaired Student t test). C, Transit time across the pulmonary circulation. Median with interquartile range
of 10 subjects (Mann-Whitney U test). D, Participants in the bronchial biopsy cohort. E, Bronchial biopsy
photomicrograph from an obese patient with asthma showing IgG1 control (top) and major basic protein
(bottom)-stained eosinophils; scale bar indicates 50 mm. F, Quantification of bronchial submucosal
eosinophil count from patients with asthma, stratified by bodymass index. Median with interquartile range
(Mann-Whitney U test). BMI, Body mass index.
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METHODS
Planar and SPECT/CT imaging of radiolabeled
eosinophils
Participants. The study was approved by the Cambridgeshire 2 Research
Ethics Committee (09/H0308/119) and the Administration of Radioactive
Substances Advisory Committee of the United Kingdom (83/3130/25000); all
subjects gave written informed consent. The subjects comprised 8 healthy
individuals, 15 patients with asthma, and 3 patients with focal pulmonary
eosinophilic inflammation (eosinophilic pneumonia, ANCA-positive
vasculitis, and IgG4-related disease) (Tables E1 and E2). Asthma was
diagnosed by a physician on the basis of symptoms, and patients with asthma
were classified according to British Thoracic Society Step classification.
Eosinophil labeling. Eosinophils were isolated from 160 mL of
autologous venous blood as described previously.E1 The eosinophils were
labeled with technetium-99m–hexamethylpropyleneamine oxime (GE
Healthcare, Buckinghamshire, UK), before reinjection into volunteers. The
ex vivo preparation time was 3.75 hours. Blood was collected at intervals
up to 9 hours postinjection and radioactivity measured in a gamma counter.
The injected activities of the radiolabeled cells were not significantly different
between the healthy individuals and patients with asthma (data not shown).
Dynamic, static, and SPECT/CT imaging. Volunteers were
positioned in a double-headed SPECT/CT camera (GE Discovery 670, GE
Healthcare), fitted with low-energy, parallel-hole collimators. After bolus
intravenous injection of technetium-99m–labeled eosinophils (mean, 120
MBq; range, 46-199 MBq injected/subject), the activities in the chest and
upper abdomenwere recorded as previously described.E1 SPECT images were
acquired over 20 minutes at 45 minutes, 2, 4, 6, and 9 hours following
reinjection. A CT scan was performed at the end of the 45-minute SPECT
acquisition for anatomical coregistration with SPECT. To generate
time-activity curves, regions of interest (ROIs) were drawn over the right
lung, the liver, and spleen using Xeleris software (Version 3.1, GE
Healthcare). Mean counts per pixel or voxel in these ROIs were recorded
and corrected for physical decay of the radionuclide. To calculate the
first-pass transit time of eosinophils, a gamma variate fit was generated
from the mean counts per pixel or voxel in the lung.E2 Gamma variate fit
was performed on 15 of 22 subjects (Fig E1), because it required a minimum
number of data points between 0 and 120 seconds after reinjection of the
radiolabeled cells.
Patlak-Rutland analysis. Peripheral blood samples were taken at 2, 4,
6, 8, 10, 15, 30, 45, 90, 120, 240, 360, and 540 minutes postinjection and
radioactivity measured in a gamma counter. ROIs were drawn over the lung on
transaxial sections of the SPECT images at each time point (Fig E2) and
average counts per voxel for each lung determined. Patlak-Rutland analysis
was used to measure pulmonary eosinophil uptake per unit pulmonary
eosinophil distribution volume by dividing the plot gradient by the intercept,
as previously described.E3-E5 Total eosinophil migration per unit pulmonary
distribution volume was calculated by multiplying the eosinophil uptake by
the average peripheral blood eosinophil count of each subject. Thesemeasures
of eosinophil blood/lung gradient are independent of the administered activity.
Quantitation of submucosal eosinophils in obese
and nonobese patients with asthma
Participants. Data were obtained from the pretreatment investigations
including bronchial biopsies of 61 subjects participating in a randomised,
double-blind, placebo-controlled trial of fevipiprant, a prostaglandin D2
receptor 2 antagonist.E6 All subjects provided written informed consent. The
study was approved by the Leicestershire, Northamptonshire, and Rutland
Research Ethics Committees (11/EM/0402) and the UK Medicines and
Healthcare Products Regulatory Agency. Details of the patient characteristics
are provided in Table E3.
Sputum, blood, and FENO sample collection. Induced sputum
(n5 59), blood (n5 61), endobronchial biopsy (n5 34), and FENO (n5 60)
were collected from visit 3 of the pretreatment phase of the fevipiprant trial.E6
Absolute eosinophil numbers in induced sputum and blood were determined
as described.E6 A cross-sectional analysis of this data, comparing asthma
patients with and without obesity, was performed and presented here for the
first time.
Measurement of submucosal eosinophils. Biopsy specimens were
embedded in glycolmethacrylate and 2-mm sections stainedwith hematoxylin
and eosin and antieosinophil major basic protein (Clone BMK-13, Monosan,
Uden, The Netherlands) as previously detailed.E7 Eosinophils were expressed
as cells/mm2 of lamina propria and as cells/mm2 of epithelium.
Statistical analysis. Blood eosinophil recovery values were calculated
as described previously.E1 Statistical analyses were performed using
GraphPad Prism (6.0d, San Diego, Calif) as detailed in the figure legends.
Data were tested for normality using the Shapiro-Wilk test. For nonparametric
data, a Mann-Whitney U test was applied and for parametric data a Student
t test was used. For categorical data, a Fisher exact test was used. A P value
of less than .05 was considered significant. Values are expressed as
mean 6 SEM or the median and interquartile range.
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FIG E1. Technetium-99m–labeled eosinophil transit across the lung. A, Representative gamma variate
function fitted to a time-activity curve. A gamma variate was fitted using a least squares residual method
to simulate the first-pass time curve for eosinophils across the lung. Data from a single representative
experiment (healthy control). B, Transit time for eosinophils to cross from the right ventricle into the
pulmonary circulation for healthy volunteers, patients with asthma, and patients with focal eosinophilic
inflammation. Data represent the median with interquartile range for 10 patients with asthma, 5 healthy
volunteers, and 3 patients with focal pulmonary eosinophilic inflammation. P values calculated using
Mann-Whitney U test.
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Lower lung ROI
Asthmatic patient Healthy volunteer 
Lower lung ROI
Mid-lung ROIMid-lung ROI
Upper lung ROIUpper lung ROI
FIG E2. SPECT image analysis of the lung ROIs. Examples of SPECT images corresponding to lower,
middle, and upper lung sections 6 hours after reinjection of technetium-99m–labeled eosinophils in a
healthy volunteer (left panel) and a patient with asthma (right panel). White lines represent lung ROI. At each
time point, ROIs were drawn from sections of lung images. Each lung section was 4.42 mm thick and,
depending on the size of the lung, the total number of sections drawn ranged from 10 to 15 at the early
time points (45 min after reinjection) to 15 to 30 at time points 6 hours and later. The first lung ROI was
drawn from the base of the lung, which was always at least 4 sections above the liver/spleen to avoid
any scatter from these organs. Sequential ROIs were then drawn up to the top of the lung. When drawing
the ROI, care was taken to avoid the signal from themediastinum and bonemarrow (vertebra, sternum, and
ribs). For consistency, the saturation of the scanwas adjusted at each time point and for each volunteer such
that the vertebral body color had changed from blue to yellow, and then to the first hint of white. This
saturation was chosen because it gave the optimal contrast between the lung and thoracic bony skeleton.
The counts from each lung section were summed and expressed as counts/voxel before Patlak-Rutland
analysis.
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FIG E3. Correlations between radiolabeled eosinophil uptake or eosinophil migration into the lung with
FEV1 (% predicted), FVC (% predicted), FENO, Z score (FEV1/FVC), and peripheral blood eosinophil count.
Correlations between radiolabeled eosinophil uptake and (A) peripheral blood eosinophil count, (B) FEV1,
(C) Z score (FEV1/FVC), (D) FVC (% predicted), and (E) FENO. Correlations between radiolabeled eosinophil
eosinophil migration and (F) FEV1 (% predicted), (G) FEV1/FVC, (H) FVC (% predicted), and (I) FENO. FVC,
forced vital capacity; PPB, parts per billion. Both FENO and spirometry results were available only for
22 of 26 subjects. P values calculated using Spearman correlation analysis (Fig E3, A and G) or Pearson
correlation analysis (Fig E3, B-F and H-I).
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FIG E4. Comparison of 45-minute blood recovery values and peripheral blood eosinophil count in the obese
and nonobese asthmatic SPECT/CT cohort, and peripheral blood eosinophil count, epithelial and sputum
eosinophil numbers, peripheral eosinophil blood count, FENO levels, and IgE levels in the obese and
nonobese asthmatic bronchial biopsy cohort. Subjects with asthma are classified by their body mass
index (kg/m2) into nonobese (<30 kg/m2) and obese (>_30 kg/m2). A, Proportion of injected
technetium-99m–labeled eosinophils remaining in the blood at 45 minutes after reinjection. Data represent
the mean6 SEM of 7 experiments for nonobese patients with asthma and 7 experiments for obese patients
with asthma. P values calculated using unpaired Student t test. B, Peripheral blood eosinophil counts in
SPECT/CT subjects with asthma stratified by BMI as described above. Data represent the median with
interquartile range of 7 subjects for nonobese patients with asthma and 7 subjects for obese patients
with asthma. P values calculated using Mann-Whitney U test. (C) Epithelial eosinophil counts, (D) sputum
eosinophil counts, (E) peripheral blood eosinophil counts, (F) FENO, and (G) IgE levels in the obese and
nonobese bronchial biopsy cohort. Data represent the median with interquartile range of 12 to 33 subjects
for nonobese patients with asthma and 13 to 28 subjects for obese patients with asthma. P values calculated
using Mann-Whitney U test. BMI, Body mass index.
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TABLE E1. Demographic and lung function of study subjects in the planar and SPECT/CT protocol
Characteristic Healthy Asthma
Focal eosinophilic
inflammation
N 8 15 3
Sex: F/M 5/3 7/8 0/3
Age (y) 64 (4) 60 (2) 57 (6)
Peripheral blood eosinophil
count (3 109/L)
0.11 (0.08 to 0.14) 0.27 (0.16 to 0.54, P 5 .0008) 0.85 (0.72 to 2.60, P 5 .012)
BMI (kg/m2)* 25 (1.46) 28 (0.82) (P 5 .04) 22 (1.76)
FENO (PPB) 14.0 (8.8 to 23.0) 25.5 (13.5 to 35.0) 11.0 (8.0 to 35.0)
FEV1 (% pred) 99.0 (88.0 to 112.0) 82.0 (70.5 to 90.3, P 5 .015) 62.0 (52.0 to 75.0, P 5 .017)
FEV1/FVC 72.0 (62.0 to 79.0) 64.5 (57.3 to 78.3) 60.0 (56.0 to 64.0)
FEV1/FVC
Z score
21.16 (21.92 to 20.23) 20.13 (24.09 to 20.03) 22.24 (22.47 to 22.01)
Smoking status
(current/previous/never)
0/2/5 0/7 (4 obese and 3 nonobese)/8 (3 obese and 4 nonobese) 1/1/1
Atopic/nonatopic 0/5 10 atopics (5 obese and 5 nonobese)/4 nonatopic
(2 obese and 2 nonobese)
1/3
Comorbidities
(no. of patients)
Cardiovascular disease (3),
depression (1), and 4 without
any stated comorbidities
Cardiovascular disease (3), gastrointestinal disease (2),
hypothyroidism (1), arthritis (1), cirrhosis (1),
anxiety (1), hernia (1), type 2 diabetes (1), and
7 without any stated comorbidities
Asthma (1); small joint
polyarthropathy (1)
BMI, Body mass index; F, female; FVC, forced vital capacity; M, male; PPB, parts per billion.
FENO and spirometry results were available for 22 of 26 subjects. Data are presented as median (interquartile range) or mean (SEM). P values were compared to the healthy
volunteer values, using Mann-Whitney U test or Student t test. Spirometric measurements were calculated using the European Community for Coal and Steel protocol, with
Z scores from the Global Lung Initiative site (http://gligastransfer.org.au/calcs/spiro.htm).E8 American Thoracic Society clinical practice guidelines state that low FENO corresponds
to <25 PPB, intermediate FENO between 25 PPB and 50 PPB, and high FENO >50 PPB in adults. Atopy status was assessed by a positive skin prick test result to 1 or more allergens
or a clear history of seasonal allergic rhinitis.
*Mean (SEM).
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TABLE E2. BTS Step classification and medication of participants with asthma in the planar dynamic and SPECT/CT protocol
BTS Asthma step
(no. of patients
in each category)
Median (range)
daily ICS dose
(mg BDP equivalent)
Oral daily
prednisolone
dose (mg)
Median (range) long-acting
b2-adrenoceptor dose/d (mg)
Therapies in addition
to prn salbutamol
(no. of patients)Formoterol Salmeterol
Step 1 (3) 0 0 0 0 Aminophylline (1)
Step 2 (1) 400 0 0 0 None
Step 3 (6) 800 (700-800) 0 24 (24-24) 0 Montelukast (2)
Step 4 (3) 1200 (1000-1200) 0 0 75 (50-100) Montelukast (1)
Tiotropium (1)
Step 5 (2) 800 (800-800) 7.5 (5-10) 24 (24-24) 0 Tiotropium (2)
Montelukast (1)
BDP, Beclometasone dipropionate; BTS, British Thoracic Society.
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TABLE E3. Clinical characteristics of the study participants from whom bronchial biopsies were collected
Characteristic
Nonobese
(BMI < 30)
Obese
(BMI >_ 30) P value n
Age (y)* 51 (3) 49 (2) .4652 61
Sex: male, n (%) 20 (60.6) 11 (39.3) .1261 61
BMI (kg/m2)* 26 (0.36) 36 (0.84) <.0001 61
Daily inhaled corticosteroid dose (mg/d)* 1267 (101) 1504 (98) .2384 61
Submucosal eosinophils (cells/mm2) 8.58 (5.91-18.84) 16.23 (12.37-29.27) .0238 34
Epithelial eosinophils (cells/mm2) 0 (0-10.5) 3.9 (0-6.3) .4919 25
Sputum eosinophil count (%) 5.8 (1.9-32.8) 4 (1.8-10.2) .1444 59
Peripheral blood eosinophil count (109/L) 0.34 (0.21-0.60) 0.25 (0.17-0.47) .2134 61
ECP (ng/mL) 31.9 (19.5-54.0) 26.8 (14.6-55.2) .5377 56
FENO (PBB) 38.3 (19.5-64.8) 27.8 (18.1-56.9) .3512 60
Total IgE (kU/L) 172 (77-440) 158 (90-352) .8120 59
Atopic/nonatopic 29/4 26/2 .6781 61
BTS Asthma step 4 (4-4) 4 (4-5) .0927 61
BMI, Body mass index; ECP, eosinophil cationic protein; PPB, parts per billion.
Data from 33 nonobese patients and 28 obese patients based on a BMI threshold of 30 are presented as median (interquartile range) unless otherwise stated; P values calculated
using Mann-Whitney U test or, for categorical data, using a Fisher exact test.
*Mean (SEM).
Beclomethasone dipropionate equivalent.
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